Infant Bacterial Therapeutics vs Circle Pharma
Side-by-side comparison of AI visibility scores, market position, and capabilities
Infant Bacterial Therapeutics (IBT) is developing live biotherapeutic Lactobacillus reuteri DSM17938 for necrotizing enterocolitis prevention in premature infants, with Phase 3 trial results expected in 2026.
About
Infant Bacterial Therapeutics (IBT) is a Swedish biopharma company developing Lactobacillus reuteri DSM17938 — a probiotic bacterial strain — as a regulated drug (live biotherapeutic product) to prevent necrotizing enterocolitis (NEC) in premature infants. NEC is a devastating gastrointestinal emergency affecting 1–7% of premature newborns, with 30% mortality and severe long-term outcomes in survivors. No approved preventive treatments exist, despite decades of evidence suggesting certain probiotic strains reduce NEC incidence.
Circle Pharma develops orally deliverable macrocycle drug candidates targeting intracellular protein-protein interactions in cancer; raised $90M Series B in 2023 led by Novo Holdings and Foresite Capital; headquartered in San Francisco;
About
Circle Pharma is a clinical-stage biopharmaceutical company founded in 2016 by Matthew Jacobson, Siegfried Bhagwati, and Grace Aldrovandi, headquartered in San Francisco, California. The company is developing a new class of therapeutics — cell-permeable macrocycles — designed to inhibit intracellular protein-protein interactions (PPIs) that have historically been considered "undruggable." Protein-protein interactions control critical cellular processes including cell division, apoptosis (programmed cell death), and gene expression. Dysregulation of these interactions drives many cancers, but their large, flat interaction surfaces are difficult to block with small molecules, and biologics (antibodies) cannot cross cell membranes to reach intracellular targets. Circle Pharma's macrocycles are medium-sized ring-shaped molecules engineered to be both cell-permeable and orally bioavailable — a combination rarely achieved — enabling them to reach and inhibit these targets.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.